Artificial Cornea Implantation Successfully Performed at Rabin Medical Center

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

January 11, 2021

Artificial cornea implantation was performed at Rabin Medical Center using the CorNeat KPro* the first artificial cornea which completely integrates with the eye wall with no reliance on donor tissue, was successfully implanted in a human.

The artificial cornea implantation surgery was performed on a bilaterally blind, 78-year-old male at Rabin Medical Center, Israel, by Professor Irit Bahar, Director of the Ophthalmology Department. Upon removal of bandages, the CorNeat KPro immediately enabled the patient to read text and recognize family members.

Professor Irit Bahar commented on the artificial cornea implantation: “The surgical procedure was straight forward and the result exceeded all of our expectations. The moment we took off the bandages was an emotional and significant moment. Moments like these are the fulfillment of our calling as doctors. We are proud of being at the forefront of this exciting and meaningful project which will undoubtedly impact the lives of millions.”

Dr. Gilad Litvin, CorNeat Vision’s Co-Founder, Chief Medical Officer, and the inventor of the CorNeat KPro, noted: “Unveiling this first implanted eye and being in that room, in that moment, was surreal. After years of hard work, seeing a colleague implant the CorNeat KPro with ease and witnessing a fellow human being regain his sight the following day was electrifying and emotionally moving, there were a lot of tears in the room. This is an extremely important milestone for CorNeat Vision, key in our journey to enable people around the world to fully enjoy their vision potential. I am grateful and honored to work with an outstanding group of people whose hard work, diligence and creativity, made this moment possible.”

Almog Aley-Raz, CorNeat Vision’s Co-Founder, Chief Executive Officer & VP R&D, noted: “The CorNeat KPro’s first-in-human implantation is just the first step in a multi-national clinical trial, geared toward attaining CE Mark, FDA Clearance and China NMPA approval. A total of 10 patients are approved for the trial at Rabin Medical Center in Israel with two additional sites planned to open this January in Canada and six others at different stages in the approval process in France, the US, and the Netherlands. Our first trial includes blind patients who are not suitable candidates for- or have failed one or more corneal transplantations. Given the exceptional visual performance of our device, the expected healing time and retention, and the fact that it cannot carry disease, we plan to initiate a second study later this year with broader indications to approve our artificial cornea as a first line treatment, displacing the use of donor tissue used in full thickness corneal transplantations.”

*The CorNeat KPro implant is designed to replace deformed, scarred or opacified corneas and is expected to fully and immediately rehabilitate the vision of corneally blind patients following a relatively simple implantation procedure. The CorNeat KPro will transform global corneal therapy and provide, for the first time, a reliable and scalable synthetic substitute to the human cornea, significantly impacting the lives of millions of people with cornea-related visual impairments and blindness.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.